cas 2368845-05-8|| where to buy methyl 2-(bromomethyl)-5-formyl-3-(trifluoromethyl)benzoate

Название продукции:methyl 2-(bromomethyl)-5-formyl-3-(trifluoromethyl)benzoate

IUPAC Name:methyl 2-(bromomethyl)-5-formyl-3-(trifluoromethyl)benzoate

: CAS：2368845-05-8; Молекулярная формула：C11H8BrF3O3; Чистота：95%+

Упаковочная единица	Доступно для заказа	Цена ($)	Количество

Только для использования в НИОКР..

Форма запроса

Химическое название

Номер CAS

Количество*

Необходимые спецификации*
(% пробы, категория материала и т.д.)

Контактное лицо*

Электронная почта*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2368845-05-8 regularly via the above email.

Дополнительные примечания

Verification code*

refresh

: Номер CAS:2368845-05-8; Молекулярная формула:C11H8BrF3O3; Точка плавления:-; Smiles-код:O=CC=1C=C(C(=O)OC)C(=C(C1)C(F)(F)F)CBr; Плотность:

: Номер в каталоге:CM1075489; Молекулярная масса:325.08; Точка кипения:; Номер Mdl:; Хранение:

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: NX-1607; Nurix disclosed the discovery and structure of NX-1607 in the First Time Disclosures session at the American Chemical Society Spring 2024 meeting in New Orleans, LA. This is the first inhibitor of CBL-B to advance into clinical studies and a prime example of Nurix’s ability to target previously undruggable E3 ligases.